To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Expedited Access to Biosimilars Act. H.R. 9661. 119th
Cong., 2nd
sess., Introduced in House July 14, 2026. https://www.govinfo.gov/app/details/BILLS-119hr9661ih.
APA
Congress, House of Representatives (2026, July 14). Expedited Access to Biosimilars Act (H.R. 9661 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr9661ih.
MLA
United States, Congress, House of Representatives. Expedited Access to Biosimilars Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr9661ih. 119th Congress, H.R. 9661, Introduced in House 14 Jul. 2026.
Bluebook
H.R.9661 - 119th Congress (2025-2026): Expedited Access to Biosimilars Act, H.R.9661, 119th Cong. (2026), https://www.govinfo.gov/app/details/BILLS-119hr9661ih.
